☰

Joyce Tsai - Publications

Affiliations: 
University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Art History, Art Criticism
Tree Info Similar researchers PubMed Report error

11/43 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, ... ... Tsai J, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders. PMID 36740140 DOI: 10.1016/j.jad.2023.01.108  0.307
2021 Loebel A, Koblan KS, Tsai J, Deng L, Fava M, Kent J, Hopkins SC. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. Journal of Affective Disorders. PMID 34614447 DOI: 10.1016/j.jad.2021.09.109  0.34
2018 Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain, Behavior, and Immunity. PMID 30102967 DOI: 10.1016/j.bbi.2018.08.009  0.335
2017 Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 29146409 DOI: 10.1016/j.jagp.2017.08.013  0.308
2017 Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. Cns Spectrums. 1-10. PMID 28357969 DOI: 10.1017/S1092852917000074  0.314
2017 Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. Cns Spectrums. 1-8. PMID 28300012 DOI: 10.1017/S1092852917000232  0.306
2017 Pikalov A, Goldberg J, Siu C, Mao Y, Tsai J, Loebel A. Lurasidone for the treatment of major depressive disorder with mixed features: do manic symptoms moderate treatment response? European Neuropsychopharmacology. 27: S831-S832. DOI: 10.1016/S0924-977X(17)31499-2  0.314
2016 Iosifescu D, Tsai J, Hsu J, Pikalov A, Loebel A. Efficacy of lurasidone in the treatment of major depression with mixed features: the value of early improvement as a predictor of short-term response during treatment of bipolar depression with lurasidone European Neuropsychopharmacology. 26: S414. DOI: 10.1016/S0924-977X(16)31381-5  0.332
2016 Nierenberg A, Tsai J, Mao Y, Pikalov A, Suppes T, Loebel A. Efficacy Of Lurasidone In Major Depression With Mixed Features: Pattern Of Improvement In Depressive And Manic Symptoms European Psychiatry. 33: S423-S423. DOI: 10.1016/j.eurpsy.2016.01.1525  0.319
2015 Iosifescu D, Tsai J, Pikalov A, Kroger H, Cucchiaro J, Loebel A. P.2.d.018 The value of early improvement as a predictor of short-term response during treatment of bipolar depression with lurasidone European Neuropsychopharmacology. 25: S421. DOI: 10.1016/S0924-977X(15)30560-5  0.303
2014 Thase M, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. P.2.d.052 Lurasidone treatment for bipolar I depression: effect on core depression symptoms European Neuropsychopharmacology. 24: S444-S445. DOI: 10.1016/S0924-977X(14)70710-2  0.315
Low-probability matches (unlikely to be authored by this person)
2017 Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A. Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. International Journal of Bipolar Disorders. 5: 9. PMID 28168632 DOI: 10.1186/s40345-017-0075-7  0.296
2015 Forester B, Sajatovic M, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy and Safety of Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study The American Journal of Geriatric Psychiatry. 23: S170-S171. DOI: 10.1016/J.JAGP.2014.12.178  0.296
2023 Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 37443386 DOI: 10.1038/s41386-023-01648-7  0.294
2017 Raison C, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A. C-Reactive Protein Effects In Patients With Bipolar Depression Treated With Lurasidone: An Exploratory Analysis Of A Placebo-Controlled Trial Frontiers in Psychiatry. 8. DOI: 10.3389/Conf.Fpsyt.2017.48.00029  0.291
2015 Sajatovic M, Forester B, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy and Tolerability of Lurasidone in Older Adults with Bipolar Depression: Analysis of Two 6-week Double-blind, Placebo-controlled Studies European Psychiatry. 30: 1136. DOI: 10.1016/S0924-9338(15)30899-3  0.289
2017 Pikalov A, Raison C, Siu C, Tsai J, Koblan K, Loebel A. Effect of the inflammatory biomarker C-reactive protein on response to lurasidone treatment in patients with bipolar depression European Neuropsychopharmacology. 27: S839. DOI: 10.1016/S0924-977X(17)31510-9  0.287
2018 Clayton AH, Tsai J, Mao Y, Pikalov A, Loebel A. Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial. The Journal of Clinical Psychiatry. 79. PMID 30086213 DOI: 10.4088/JCP.18m12132  0.286
2020 Goldberg JF, Siu C, Mao Y, Tsai J, Pikalov A, Calabrese JR, Loebel A. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. Journal of Affective Disorders. 277: 1045-1054. PMID 33065813 DOI: 10.1016/j.jad.2020.08.048  0.285
2015 Forester B, Sajatovic M, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study European Psychiatry. 30: 1134. DOI: 10.1016/S0924-9338(15)30897-X  0.281
2016 Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. The Journal of Clinical Psychiatry. PMID 27529375 DOI: 10.4088/JCP.15m10261  0.28
2015 Sajatovic M, Forester B, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Older Adults with Bipolar Depression: Analysis of Two Double-blind, Placebo-controlled Studies The American Journal of Geriatric Psychiatry. 23: S171. DOI: 10.1016/J.JAGP.2014.12.179  0.279
2015 Sajatovic M, Forester B, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A. P.2.d.016 Lurasidone for older adults with bipolar depression: analysis of two double-blind, placebo-controlled studies European Neuropsychopharmacology. 25: S420. DOI: 10.1016/S0924-977X(15)30558-7  0.279
2022 Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, ... ... Tsai J, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England Journal of Medicine. 387: 1637-1648. PMID 36322843 DOI: 10.1056/NEJMoa2206443  0.278
2016 Nelson C, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features: effect of baseline depression severity on clinical outcome European Neuropsychopharmacology. 26: S400-S401. DOI: 10.1016/S0924-977X(16)31360-8  0.275
2015 Ketter T, Tsai J, Silva R, Kroger H, Cucchiaro J, Loebel A. P.2.d.017 Lurasidone in the long-term treatment of patients with bipolar i disorder: responder and remitter status during a 24-week open-label extension study European Neuropsychopharmacology. 25: S420-S421. DOI: 10.1016/S0924-977X(15)30559-9  0.248
2020 Grilo CM, McElroy SL, Hudson JI, Tsai J, Navia B, Goldman R, Deng L, Kent J, Loebel A. Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Placebo-controlled, Fixed-dose Clinical Trial. Cns Spectrums. 1-25. PMID 32423512 DOI: 10.1017/S1092852920001406  0.248
2017 Pikalov A, Tsai J, Mao Y, Cucchiaro J, Loebel A. Lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder: effectiveness of up to 20 weeks of treatment European Neuropsychopharmacology. 27: S825-S826. DOI: 10.1016/S0924-977X(17)31491-8  0.239
2015 Newcomer J, Tsai J, Pikalov A, Kroger H, Cucchiaro J. Effect of Lurasidone On Metabolic Parameters in Patients with Bipolar Depression European Psychiatry. 30: 1140. DOI: 10.1016/S0924-9338(15)30902-0  0.235
2017 Pikalov A, Goldberg J, Mao Y, Siu C, Tsai J, Calabrese J, Loebel A. Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features: Do Manic Symptoms Moderate Treatment Response? European Psychiatry. 41: s243-s243. DOI: 10.1016/j.eurpsy.2017.02.018  0.234
2012 Bose A, Tsai J, Li D. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clinical Drug Investigation. 32: 373-85. PMID 22559255 DOI: 10.2165/11631890-000000000-00000  0.234
2020 Tsai J, Navia B, McElroy SL, Hudson JI, Grilo CM, Goldman R, Deng L, Kent J, Loebel A. 170 Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial. Cns Spectrums. 25: 308-309. PMID 32331033 DOI: 10.1017/S1092852920000863  0.22
2020 Citrome L, Goldman R, Tsai J, Deng L, Grinnell T, Pikalov A. 169 Dasotraline for Treatment of Adults with Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions. Cns Spectrums. 25: 307-308. PMID 32331062 DOI: 10.1017/S1092852920000851  0.21
2019 Rabinowitz J, Schooler NR, Brown B, Dalsgaard M, Engelhardt N, Friedberger G, Kinon BJ, Lee D, Ockun F, Mahableshwarkar A, Tsai J, Williams JBW, Sauder C, Yavorsky C. Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). Journal of Affective Disorders. 256: 143-147. PMID 31176186 DOI: 10.1016/j.jad.2019.05.077  0.183
2020 Citrome L, Goldman R, Tsai J, Deng L, Grinnell T, Pikalov A. 168 Effect of Dasotraline on Body Weight in Patients with Binge-Eating Disorder. Cns Spectrums. 25: 307. PMID 32331079 DOI: 10.1017/S109285292000084X  0.155
2021 Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Nosaka T, Higuchi T. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry and Clinical Neurosciences. PMID 33890388 DOI: 10.1111/pcn.13221  0.149
2021 Iyo M, Ishigooka J, Nakamura M, Sakaguchi R, Okamoto K, Mao Y, Tsai J, Fitzgerald A, Takai K, Higuchi T. Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatric Disease and Treatment. 17: 2683-2695. PMID 34429604 DOI: 10.2147/NDT.S320021  0.147
2013 Tsai J, Krueger J, Maines C. "Transparency and light, structure and substance": Enamel paints in László Moholy-Nagy's Z VII (1926) Journal of the American Institute For Conservation. 52: 236-245. DOI: 10.1179/1945233013Y.0000000017  0.147
2019 Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J, Hsu J, Loebel A, Goldman R. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. Journal of Attention Disorders. 1087054719864644. PMID 31375051 DOI: 10.1177/1087054719864644  0.134
2022 Wigal S, Tsai J, Bates JA, Sarma K, Tortorich D, Zhu H, Goldman R. A Randomized, Placebo-Controlled Laboratory Classroom Study of the Efficacy and Safety of Dasotraline in Children With ADHD. Journal of Attention Disorders. 10870547211073477. PMID 35048745 DOI: 10.1177/10870547211073477  0.121
2020 Miller BJ, Pikalov A, Siu CO, Tocco M, Tsai J, Harvey PD, Newcomer JW, Loebel A. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry. 102: 152195. PMID 32896775 DOI: 10.1016/J.Comppsych.2020.152195  0.121
2019 Miller B, Pikalov A, Siu C, Tocco M, Tsai J, Harvey P, Loebel A. Inflammatory markers and cognitive performance in patients with schizophrenia treated with lurasidone European Neuropsychopharmacology. 29: S416-S417. DOI: 10.1016/J.Euroneuro.2018.11.631  0.079
2018 Pikalov A, Miller B, Siu C, Tocco M, Tsai J, Harvey P, Loebel A. F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE Schizophrenia Bulletin. 44: S242-S243. DOI: 10.1093/schbul/sby017.591  0.078
Hide low-probability matches.